Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic β-cells

Endocrinology

Volumn 150, Issue 10, 2009, Pages 4521-4530

  Rütti, Sabine ^a,b   Ehses, Jan A ^a   Sibler, Rahel A ^a   Prazak, Richard ^a   Rohrer, Lucia ^a,b   Georgopoulos, Spiros ^c   Meier, Daniel T ^a   Niclauss, Nadja ^d   Thierry, Berney ^d   Donath, Marc Y ^a   Von Eckardstein, Arnold ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^d UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN RECEPTOR; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; SPHINGOSINE 1 PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; EXPERIMENTAL MOUSE; FEMALE; HUMAN; INSULIN RELEASE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ANTIGENS, CD95; APOLIPOPROTEIN A-I; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; FEMALE; GLUCOSE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; INTERLEUKIN-1BETA; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, LDL; SCAVENGER RECEPTORS, CLASS B; SPHINGOSINE;

EID: 70349320177     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-0252     Document Type: Article

References (34)

1. Donath MY, Halban PA 2004 Decreased β-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 47:581-589 (Pubitemid 38491259)
2. Kahn SE, Hull RL, Utzschneider KM 2006 Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-846 (Pubitemid 46024990)
3. Prentki M, Nolan CJ 2006 Islet β cell failure in type 2 diabetes. J Clin Invest 116:1802-1812 (Pubitemid 44033300)
4. Shepherd J 2007 Dyslipidaemia in diabetic patients: time for a re-think. Diabetes Obes Metab 9:609-616 (Pubitemid 47261843)
5. von Eckardstein A, Schulte H, Assmann G 2000 Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Munster. J Clin Endocrinol Metab 85:3101-3108 (Pubitemid 30944510)
6. Roehrich ME, Mooser V, Lenain V, Herz J, Nimpf J, Azhar S, Bideau M, Capponi A, Nicod P, Haefliger JA, Waeber G 2003 Insulin-secreting β-cell dysfunction induced by human lipoproteins. J Biol Chem 278:18368-18375 (Pubitemid 36799458)
7. Brunham LR, Kruit JK, Verchere CB, Hayden MR 2008 Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest 118:403-408 (Pubitemid 351206525)
8. Abderrahmani A, Niederhauser G, Favre D, Abdelli S, Ferdaoussi M, Yang JY, Regazzi R, Widmann C, Waeber G2007 Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic β cells. Diabetologia 50:1304-1314
9. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR 2007 β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 13:340-347 (Pubitemid 46376682)
10. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY 2002 Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110:851-860 (Pubitemid 35050963)
11. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY 2007 Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517-1526 (Pubitemid 46588416)
12. Argraves KM, Argraves WS 2007 HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res 48:2325-2333
13. Havel RJ, Eder HA, Bragdon JH 1955 The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345-1353
14. von Eckardstein A, Funke H, Walter M, Altland K, Benninghoven A, Assmann G 1990 Structural analysis of human apolipoprotein A-I variants. Amino acid substitutions are nonrandomly distributed throughout the apolipoprotein A-I primary structure. J Biol Chem 265:8610-8617 (Pubitemid 20167371)
15. Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von Eckardstein A, Seedorf U, Assmann G 2001 Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276:34480-34485 (Pubitemid 37384437)
16. Miettinen HE, Rayburn H, Krieger M 2001 Abnormal lipoprotein metabolism and reversible female infertility in HDL receptor (SR-BI)-deficient mice. J Clin Invest 108:1717-1722 (Pubitemid 33144881)
17. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, Gueripel X, Ellingsgaard H, Schneider MK, Biollaz G, Fontana A, Reinecke M, Homo-Delarche F, Donath MY 2007 Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56:2356-2370 (Pubitemid 47358243)
18. Ellingsgaard H, Ehses JA, Hammar EB, Van Lommel L, Quintens R, Martens G, Kerr-Conte J, Pattou F, Berney T, Pipeleers D, Halban PA, Schuit FC, Donath MY 2008 Interleukin-6 regulates pancreatic α-cell mass expansion. Proc Natl Acad Sci USA 105:13163-13168
19. Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T, Dayer JM, Reinecke M, Halban PA, Donath MY 2004 Leptin modulates β cell expression of IL-1 receptor antagonist and release of IL-1β in human islets. Proc Natl Acad Sci USA 101:8138-8143 (Pubitemid 38698067)
20. Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A, Kaiser N, Donath MY 2001 Glucose induces β-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 50:1683-1690 (Pubitemid 33641583)
21. Vohl MC, Gaudet D, Moorjani S, Tremblay G, Perron P, Gagné C, Lesie'ge D, Bergeron J, Lupien PJ, Després JP 1997 Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia. Eur J Clin Invest 27:366-3 73
22. Skoumas I, Masoura C, Pitsavos C, Tousoulis D, Papadimitriou L, Aznaouridis K, Chrysohoou C, Giotsas N, Toutouza M, Tentolouris C, Antoniades C, Stefanadis C 2007 Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. Int J Cardiol 121:178-183 (Pubitemid 47379454)
23. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195-2207
24. Coleman CI, Reinhart K, Kluger J, White CM 2008 The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin 24:1359-1362 (Pubitemid 351741567)
25. Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW 2007 Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic β-cell dysfunction. Diabetes 56:2328-2338 (Pubitemid 47358240)
26. Locher R, Brandes RP, Vetter W, Barton M 2002 Native LDL induces proliferation of human vascular smooth muscle cells via redox-mediated activation of ERK 1/2 mitogen-activated protein kinases. Hypertension 39:645-650 (Pubitemid 34165199)
27. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW 2007 Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117:746-756 (Pubitemid 46348533)
28. Wiesner P, Leidl K, Boettcher A, Schmitz G, Liebisch G 2009 Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res 50:574-585
29. Laychock SG, Sessanna SM, Lin MH, Mastrandrea LD 2006 Sphingosine 1-phosphate affects cytokine-induced apoptosis in rat pancreatic islet β-cells. Endocrinology 147:4705-4712
30. Gupta H, Dai L, Datta G, Garber DW, Grenett H, Li Y, Mishra V, Palgunachari MN, Handattu S, Gianturco SH, Bradley WA, Anantharamaiah GM, White CR 2005 Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 97:236-243 (Pubitemid 41105449)
31. Størling J, Binzer J, Andersson AK, Züllig RA, Tonnesen M, Lehmann R, Spinas GA, Sandler S, Billestrup N, Mandrup-Poulsen T 2005 Nitric oxide contributes to cytokine-induced apoptosis in pancreatic β cells via potentiation of JNK activity and inhibition of Akt. Diabetologia 48:2039-2050 (Pubitemid 41416915)
32. Li XA, Guo L, Dressman JL, Asmis R, Smart EJ 2005 A novel ligand-independent apoptotic pathway induced by scavenger receptor class B, type I and suppressed by endothelial nitric-oxide synthase and high density lipoprotein. J Biol Chem 280:19087-19096 (Pubitemid 41379615)
33. Kimura T, Sato K, Kuwabara A, Tomura H, Ishiwara M, Kobayashi I, Ui M, Okajima F 2001 Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 276:31780-31785 (Pubitemid 37384826)
34. Laychock SG, Tian Y, Sessanna SM 2003 Endothelial differentiation gene receptors in pancreatic islets and INS-1 cells. Diabetes 52:1986-1993 (Pubitemid 36919790)